STEPP: A Phase 2, Open-Label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-Line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab.

Trial Profile

STEPP: A Phase 2, Open-Label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-Line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Panitumumab (Primary) ; Doxycycline; Fluorouracil; Folinic acid; Hydrocortisone; Irinotecan; Sunscreens
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Registrational
  • Acronyms STEPP
  • Sponsors Amgen
  • Most Recent Events

    • 06 Jun 2017 Results from STEPP and J-STEPP studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2009 New trial record.
    • 29 May 2009 Final quality-of-life results for prophylactic versus reactive skin toxicity treatment presented at ASCO 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top